Dow Jones Newswires: Novartis hemoglobinuria trial meets two primary endpoints

by | Oct 24, 2022 | Stock Market

Novartis AG
NOVN,
+0.47%

NVS,
+2.05%
said Monday that a study on a drug to treat adult paroxysmal nocturnal hemoglobinuria, a red blood cell condition, has met its two primary endpoints. The trial studied a drug named Iptacopan and established its superiority to a previously used treatment in helping patients with debilitating anemia who would normally undergo blood transfusions, according to the company.

“Iptacopan was well tolerated with a favorable safety profile consistent with previously reported data,” Novartis said. Write to Cecilia Butini at cecilia.butini@wsj.com

Article Attribution | Read More at Article Source

Share This